SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is currently facing significant volatility as investors brace for the upcoming FDA Advisory Committee meeting to evaluate the clinical efficacy of its DMD therapy. The community is sharply divided, with bulls pointing to robust Phase 3 data and strong support from the patient advocacy community, while bears are citing regulatory skepticism, insider selling, and potential patent litigation as major headwinds.

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is currently the subject of intense retail speculation and volatility as investors debate the impact of upcoming share lock-up expirations against the company's long-term aerospace and AI infrastructure ambitions. Community sentiment remains sharply divided between bulls focused on successful flight milestones and long-term tech integration, and skeptics who are concerned about excessive valuation and potential selling pressure from institutional insiders.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending following an agreement to expand its use of quantum computing technology across AT&T's network operations, a move aimed at enhancing optimization and network efficiency. While the stock has seen volatility as part of a broader macro-driven unwind in high-beta tech, the community is actively debating the company's long-term enterprise traction and valuation against its upcoming quarterly earnings report.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros shares are trending as investors weigh potential market competition following an AstraZeneca trial result while looking ahead to key milestones like CMS reimbursement updates and EMA re-examination. The community is actively debating the significance of recent Symphony prescription data and its impact on the company's valuation versus long-term growth prospects.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is attracting intense investor attention following new executive orders aimed at accelerating U.S. quantum technology leadership and security infrastructure. While the community is actively debating the stock's long-term potential versus concerns over high valuations and insider selling, traders are closely monitoring how these government-linked catalysts will impact near-term momentum.

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. Its lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner on May 3, 2017 and is headquartered in Dallas, TX.

Forte Biosciences Inc

Forte Biosciences is trending following a definitive agreement for its acquisition by Argenx in an all-cash transaction valued at $77 per share. The community is actively discussing the significant premium offered over recent volume-weighted average prices, with many noting that the market appears to be treating the acquisition as a near-certainty given the current trading proximity to the offer price.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is currently at the center of investor discussion following reports of a massive $500 billion multi-year AI infrastructure partnership with SK Group and ongoing talks regarding a $250 billion financing guarantee for an OpenAI data center project. While some community members view these expansive deals as validation of long-term AI infrastructure demand, others are expressing concern over the implications of such large-scale financing arrangements and continued bearish sentiment from high-profile investors.

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

Legend Biotech Corp - ADR

Legend Biotech

Legend Biotech is trending due to a steep sell-off following the release of J&J's competitor data in the multiple myeloma space, which has triggered concerns about market share and future competitive pressure for the company's flagship therapy, Carvykti. Community discourse remains deeply divided, with some investors panic-selling due to the technical breakdown, while others aggressively accumulate shares, citing a massive disconnect between current price levels and the company's underlying fundamentals, cash position, and long-term M&A potential.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending as investors position themselves ahead of upcoming Q2 earnings and anticipated data readouts for its NSCLC and melanoma programs. The community is actively debating the stock's long-term valuation, potential acquisition interest, and the impact of significant short interest as price action shows signs of institutional accumulation.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is facing intense downward pressure and regulatory uncertainty as 12 states have filed a lawsuit to block its merger with Warner Bros. Discovery, prompting concerns over potential deal delays and associated financial penalties. While community sentiment remains divided between fears of further dilution and strong belief in a potential long-term recovery, many investors are closely tracking the company's legal defense as a critical catalyst to determine if the deal can successfully close.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


xoso66bz

Nhà Cái XOSO66